SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)

Rhea-AI Summary

SIGA Technologies, Inc. (SIGA) announced approximately $16 million in international procurement orders for oral TPOXX® (tecovirimat) in August and early September 2022. This includes a $10 million order from the European Commission for emergency stockpiling related to the monkeypox outbreak, funded by HERA. Additionally, two orders totaling $6 million were received from the Asia Pacific region. SIGA expects to deliver at least $65 million of orders in 2022, contributing to addressing the ongoing monkeypox crisis.

Positive

• Received approximately $16 million in international orders for TPOXX.
• Secured a $10 million order from the European Commission for emergency stockpiling.
• Anticipates delivering $65 million of orders in 2022.

Negative

• None.

   - Order for Approximately $10 Million Funded by the European Commission –

- Orders for Approximately $6 Million Received from Two Countries in the Asia Pacific Region -

NEW YORK, Sept. 26, 2022 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced receipt of approximately $16 million of international procurement orders for oral TPOXX® (tecovirimat) in August and early September, including an approximate $10 million order by the European Commission, through funds from the European Health Emergency Preparedness and Response Authority (HERA) and implemented via rescEU, and approximately $6 million of orders from two countries in the Asia Pacific region, one of which is a new customer.  

The order from the European Commission is for emergency short-term stockpiling and/or deployment of oral TPOXX (tecovirimat) in connection with the monkeypox outbreak. In addition to procuring oral TPOXX through the funding of direct purchases, the European Commission is also coordinating country-level procurement through the use of a joint procurement mechanism. SIGA and its international promotion partner, Meridian Medical Technologies, LLC, will continue to pursue multiple paths of coordinating European Union health security.

SIGA expects to complete delivery of these most recent orders in 2022. To date this year, including the recent orders, SIGA has received approximately $76 million of international orders for oral TPOXX (tecovirimat) from twelve international customers. It is currently expected that at least $65 million of these orders will be delivered in 2022.

“With over 64,000 global cases of monkeypox since May 2022, individual countries as well as pan-international government organizations and non-governmental organizations (NGOs) have become increasingly focused on addressing the monkeypox outbreak,” said Phil Gomez, CEO of SIGA. “Procurement of TPOXX by the European Commission and by individual countries represent important steps in addressing the near-term risks of the monkeypox outbreak and toward acknowledging and preparing for the longer-term risks posed by the family of orthopox viruses.”

ABOUT SIGA TECHNOLOGIES, INC. and TPOXX®

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX under Project BioShield. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox in 2018, and the IV formulation was approved for the same indication in 2022. The full label is available by clicking here. Oral tecovirimat received approval from the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom in 2022. The EMA and UK approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. The full label is available by clicking here. In September 2018, SIGA signed a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, for additional procurement and development related to both oral and intravenous formulations of TPOXX. For more information about SIGA, please visit www.siga.com.

ABOUT MERIDIAN MEDICAL TECHNOLOGIES, LLC

Meridian Medical Technologies, LLC is a leader in the global heath security market with more than 60 years of experience in providing medical countermeasures to both military and civilian defenders. Meridian has extensive experience working with government agencies in the United States and around the globe addressing preparedness needs and stockpiling requirements for chemical and biological threats. Meridian is committed to protecting those who protect others, whether they are deployed military personnel or civilian emergency responders/healthcare workers, by providing medical countermeasures for rapid and effective response in time-sensitive, life-or-death situations.

About Smallpox

Smallpox is a contagious, disfiguring and often deadly disease that has affected humans for thousands of years. Naturally-occurring smallpox was eradicated worldwide by 1980, the result of an unprecedented global immunization campaign. Samples of smallpox virus have been kept for research purposes. This has led to concerns that smallpox could someday be used as a biological warfare agent. A vaccine can prevent smallpox, but the risk of the current vaccine's side effects is too high to justify routine vaccination for people at low risk of exposure to the smallpox virus.

About Monkeypox

Monkeypox is a disease caused by infection with the monkeypox virus. Monkeypox virus is part of the same family of viruses as smallpox. Monkeypox symptoms are similar to smallpox, but not as severe and with historical fatality in Africa of less than 1% to 10% depending on region and clade.  The first human case of monkeypox was recorded in 1970. Since then, monkeypox has been reported in several central and western African countries, with case numbers greatly increasing in recent years. Prior to the ongoing 2022 outbreak, nearly all monkeypox cases in people outside of Africa were linked to international travel to countries where the disease commonly occurs, or through imported animals, including two cases in the United States in 2021. These cases are currently occurring on multiple continents.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements relating to the progress of SIGA’s development programs and timelines for bringing products to market, delivering products to the Strategic Stockpile, the enforceability of our procurement contracts, such as the 19C BARDA Contract (the "BARDA Contracts"), with BARDA, the impact of the COVID pandemic and responding to the global outbreak of monkeypox. The words or phrases “can be,” “expects,” “may affect,” “may depend,” “believes,” “estimate,” “project” and similar words and phrases are intended to identify such forward-looking statements. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. SIGA’s actual results could differ materially from those anticipated by such forward-looking statements due to a number of factors, some of which are beyond SIGA’s control, including, but not limited to, (i) the risk that BARDA elects, in its sole discretion as permitted under the BARDA Contracts, not to exercise all, or any, of the remaining unexercised options under those contracts, (ii) the risk that SIGA may not complete performance under the BARDA Contracts on schedule or in accordance with contractual terms, (iii) the risk that the BARDA Contracts are modified or canceled at the request or requirement of the U.S. Government, (iv) the risk that the nascent international biodefense market does not develop to a degree that allows SIGA to successfully market TPOXX® internationally, (v) the risk that potential products, including potential alternative uses or formulations of TPOXX® that appear promising to SIGA or its collaborators, cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (vi) the risk that SIGA or its collaborators will not obtain appropriate or necessary governmental approvals to market these or other potential products or uses, (vii) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including intellectual property protection, (viii) the risk that any challenge to SIGA’s patent and other property rights, if adversely determined, could affect SIGA’s business and, even if determined favorably, could be costly, (ix) the risk that regulatory requirements applicable to SIGA’s products may result in the need for further or additional testing or documentation that will delay or prevent SIGA from seeking or obtaining needed approvals to market these products, (x) the risk that the volatile and competitive nature of the biotechnology industry may hamper SIGA’s efforts to develop or market its products, (xi) the risk that changes in domestic or foreign economic and market conditions may affect SIGA’s ability to advance its research or may affect its products adversely, (xii) the effect of federal, state, and foreign regulation, including drug regulation and international trade regulation, on SIGA’s businesses, (xiii) the risk of disruptions to SIGA’s supply chain for the manufacture of TPOXX®, causing delays in SIGA’s research and development activities, causing delays or the re-allocation of funding in connection with SIGA’s government contracts, or diverting the attention of government staff overseeing SIGA’s government contracts, (xiv) the risk that the U.S. or foreign governments' responses (including inaction) to national or global economic conditions or infectious diseases, such as COVID-19, are ineffective and may adversely affect SIGA’s business, and (xv) risks associated with responding to the current monkeypox outbreak, as well as the risks and uncertainties included in Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2021 and SIGA's subsequent filings with the Securities and Exchange Commission. SIGA urges investors and security holders to read those documents free of charge at the SEC's website at http://www.sec.gov. All such forward-looking statements are current only as of the date on which such statements were made. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.

Contacts:
Investor Contact
Laine Yonker, Edison Group
lyonker@edisongroup.com 

Michael Crawford, Edison Group
mcrawford@edisongroup.com 

Public Relations
Holly Stevens, Berry & Company
hstevens@berrypr.com

FAQ

What is SIGA's recent order total for TPOXX?

SIGA announced approximately $16 million in international procurement orders for TPOXX.

Who funded SIGA's $10 million order?

The $10 million order from the European Commission was funded by HERA.

What is the expected delivery amount for SIGA in 2022?

SIGA expects to deliver at least $65 million in orders for TPOXX in 2022.

What is TPOXX used for?

TPOXX is used for emergency stockpiling related to the monkeypox outbreak.

When did SIGA receive the international orders for TPOXX?

The orders were received in August and early September 2022.